Skip to main content

Table 2 Gallbladder cancer: prior therapy , concurrent chemotherapy, and treatment duration

From: HER2/neu-directed therapy for biliary tract cancer

Pt #

Sites of disease

Prior therapy

HER2/neu test

HER2/neu therapy

Concurrent therapy

Duration of therapy (weeks)

Overall survival (weeks)

Best response

1

Bone, liver

Nil

IHC 3+

Trastuzumab

Gemcitabine, cisplatin

7

20

SD

2

Peritoneum, lung, liver

Gemcitabine + cisplatin, FOLFIRI + erbitux

Mutation (NGS) V777L

Lapatinib

Sirolimus

15

19

MR

3

Retroperitoneal LN, liver

Nil

FISH amplification

Trastuzumab

Nil

38

113

CR

4

Liver

Gemcitabine + cisplatin, capecitabine, FOLFOX

ERBB2 NGS amplification

Trastuzumab

Gemcitabine + irinotecan

40

62

PR

5

Liver, LN

Gemcitabine + cisplatin

ERBB2 NGS amplification

Trastuzumab

FOLFOX capecitabine

92

92

PR

6

Sternum, pleura, lung

Gemcitabine, capecitabine

AMPLIFIED (FISH)

Trastuzumab

 

168

178

PR

7

Retroperitoneal LN, celiac LN

Nil

AMPLIFIED (FISH)

Trastuzumab

Gemcitabine + cisplatin

22+

22+

PR

8

Retroperitoneal LN, supraclavicular LN

Gemcitabine + capecitabine, gemcitabine + cisplatin, pazopanib, dovitinib

ERBB2 NGS amplification

Trastuzumab + pertuzumab

Nil

8+

8+

SD

9

Lungs, brain

Gemcitabine + cisplatin radiation

IHC 3+

Trastuzumab

Paclitaxel capecitabine

72

96+

PR

  1. HER2-positive tumors IHC 3+, FISH HER2/centromere 17 ratio ≥2.0 or both
  2. SD stable disease, MR mixed response, PR partial response